Emil D. Kakkis, President & CEO at Ultragenyx Pharmaceutical Inc. (RARE), sold 30,000 shares at $107.80 ($3.2M) on 2021-05-03, disclosed to the SEC on 2021-05-05.
Seasonal sale ($3.2M) by President & CEO — this insider has traded RARE in May in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| RARE | SELL | 2024-12-31 | $990K | — | Filing → |
| RARE | SELL | 2024-12-11 | $414K | — | Filing → |
| RARE | SELL | 2024-09-05 | $1.1M | — | Filing → |